Kolkisin Tiofarma (Colchicine)

Colchicine binds to tubulin, preventing the formation of microtubules. This blocks neutrophil migration, adhesion, and degranulation, which are key steps in the inflammatory cascade triggered by urate crystals in gout and by innate immune activation in familial Mediterranean fever.

The specific dose of Kolkisin Tiofarma is determined by the prescribing clinician based on the patient’s condition, renal and hepatic function, and other individual factors. Healthcare professionals should follow current clinical guidelines and adjust the regimen as needed.

Colchicine is classified as a pregnancy‑category drug with limited safety data. It should only be used if the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should consult their physician, as colchicine may be excreted in breast milk.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with NSAIDs or corticosteroids, colchicine offers a non‑steroidal anti‑inflammatory option that can be used for both acute attacks and long‑term prophylaxis. Unlike newer urate‑lowering agents such as febuxostat, colchicine does not reduce serum uric acid but directly suppresses the inflammatory response.

Kolkisin Tiofarma should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, excessive heat and direct sunlight to maintain its stability and potency.

The medication is taken orally, usually with a full glass of water. It may be taken with or without food, depending on the prescriber’s instructions. Patients should follow the dosing schedule provided by their healthcare professional.

The most serious risks include bone‑marrow suppression leading to neutropenia or aplastic anemia, severe muscle toxicity such as rhabdomyolysis, and life‑threatening organ failure in cases of overdose. Prompt medical attention is required if these symptoms appear.

Colchicine should be avoided in patients with severe hepatic impairment, advanced renal failure (eGFR < 30 mL/min), known hypersensitivity to colchicine, and in individuals taking contraindicated strong CYP3A4 or P‑glycoprotein inhibitors. Clinicians must assess each patient’s medical history before prescribing.